Golden age of immunoengineering.
作者信息
Wong Wilson W, Lim Wendell A
机构信息
Biomedical Engineering and Biological Design Center, Boston University, Boston, Massachusetts, USA.
Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, California, USA.
出版信息
Immunol Rev. 2023 Nov;320(1):4-9. doi: 10.1111/imr.13283. Epub 2023 Oct 23.
Abstract
摘要
相似文献
1
Golden age of immunoengineering.
Immunol Rev. 2023 Nov;320(1):4-9. doi: 10.1111/imr.13283. Epub 2023 Oct 23.
2
Immunotherapy and immunoengineering for breast cancer; a comprehensive insight into CAR-T cell therapy advancements, challenges and prospects.
Cell Oncol (Dordr). 2022 Oct;45(5):755-777. doi: 10.1007/s13402-022-00700-w. Epub 2022 Aug 9.
3
Nano-optogenetic immunotherapy.
Clin Transl Med. 2022 Sep;12(9):e1020. doi: 10.1002/ctm2.1020.
4
Immunoengineering with biomaterials for enhanced cancer immunotherapy.
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2018 Jul;10(4):e1506. doi: 10.1002/wnan.1506. Epub 2018 Jan 14.
5
CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
Hum Immunol. 2018 Dec;79(12):876-882. doi: 10.1016/j.humimm.2018.09.007. Epub 2018 Sep 24.
6
Mechanical Immunoengineering of T cells for Therapeutic Applications.
Acc Chem Res. 2020 Dec 15;53(12):2777-2790. doi: 10.1021/acs.accounts.0c00486. Epub 2020 Dec 1.
7
Nanotechnology and immunoengineering: How nanotechnology can boost CAR-T therapy.
Acta Biomater. 2020 Jun;109:21-36. doi: 10.1016/j.actbio.2020.04.015. Epub 2020 Apr 13.
8
Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T.
Mol Cancer. 2023 Feb 7;22(1):28. doi: 10.1186/s12943-023-01735-9.
9
CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy.
J Exp Clin Cancer Res. 2021 Aug 26;40(1):269. doi: 10.1186/s13046-021-02076-5.
10
Nanobody-based chimeric antigen receptor T cells designed by CRISPR/Cas9 technology for solid tumor immunotherapy.
Signal Transduct Target Ther. 2021 Feb 25;6(1):80. doi: 10.1038/s41392-021-00462-1.
本文引用的文献
1
"Hurdles race for CAR T-cell therapy in digestive tract cancer".
Immunol Rev. 2023 Nov;320(1):100-119. doi: 10.1111/imr.13273. Epub 2023 Sep 11.
2
Coengineering specificity, safety, and function into T cells for cancer immunotherapy.
Immunol Rev. 2023 Nov;320(1):166-198. doi: 10.1111/imr.13252. Epub 2023 Aug 7.
3
Next-generation chimeric antigen receptors for T- and natural killer-cell therapies against cancer.
Immunol Rev. 2023 Nov;320(1):217-235. doi: 10.1111/imr.13255. Epub 2023 Aug 7.
4
Eras of designer Tregs: Harnessing synthetic biology for immune suppression.
Immunol Rev. 2023 Nov;320(1):250-267. doi: 10.1111/imr.13254. Epub 2023 Jul 31.
5
Toward the clinical development of synthetic immunity to cancer.
Immunol Rev. 2023 Nov;320(1):83-99. doi: 10.1111/imr.13245. Epub 2023 Jul 25.
6
A synthetic biology approach to engineering circuits in immune cells.
Immunol Rev. 2023 Nov;320(1):120-137. doi: 10.1111/imr.13244. Epub 2023 Jul 19.
7
Challenges and solutions for therapeutic TCR-based agents.
Immunol Rev. 2023 Nov;320(1):58-82. doi: 10.1111/imr.13233. Epub 2023 Jul 16.
8
Applications of CRISPR technology in cellular immunotherapy.
Immunol Rev. 2023 Nov;320(1):199-216. doi: 10.1111/imr.13241. Epub 2023 Jul 14.
9
Harnessing the power of artificial intelligence to advance cell therapy.
Immunol Rev. 2023 Nov;320(1):147-165. doi: 10.1111/imr.13236. Epub 2023 Jul 6.
10
Spatiotemporally programming cytokine immunotherapies through protein engineering.
Immunol Rev. 2023 Nov;320(1):10-28. doi: 10.1111/imr.13234. Epub 2023 Jul 6.
Zotero 插件